



July 31, 2012

Company Name	3 - D M a t r i x , L t d .
A d d r e s s	3-2-4, Kojimachi, Chiyoda, Tokyo
P r e s i d e n t	Kentaro Takamura
Code Number	7777
C o n t a c t	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

**3-D Matrix nominated as a joint research partner  
in Grants-in Aid for Scientific Research Project  
on non-clinical study for innovative cancer treatment**

3-D Matrix, Ltd. (3DM) was nominated by Ministry of Health, Labour, and Welfare as a joint partner with National Cancer Center Hospital (Chief Physician: Akira Kawai) and National Cancer Center Research Institute (Chief, Division of Molecular and Cellular Medicine: Takahiro Ochiya) for a project of Grants-in-Aid for Scientific Research on non-clinical study for innovative cancer treatment.

This research project is targeted on osteosarcoma and intended to put nucleic acid medicine for a targeted micro RNA which controls cancer stem cell of osteosarcoma into clinical use. The treatment of osteosarcoma, which many patients including children have been suffering from, has had little progress in recent 20 years. This nucleic acid medicine destroying cancer stem cell is expected to contribute toward an innovative treatment to improve vital prognosis of patients. At National Cancer Center Research Institute, the target micro RNA which controls cancer stem cell has been identified and resistance to anticancer drug has been confirmed to be reduced by controlling the micro RNA with an inhibitor.

Promoting preclinical study in this project leads to verifying safety and efficacy for spontaneous osteosarcoma and will influence not only global but also research of cancer stem cells, micro RNAs, and those clinical development osteosarcoma treatment. Since we have already started, a joint project with 3DM and National Cancer Center which aims to start a first-in-human clinical trial for breast cancer using nucleic acid medicine controlling cancer stem cell, it is expected to make great synergy with this project.

This nomination will give a research and development grant to the project itself and does not influence the earning forecast of 3DM at this moment.

3DM promotes research and development of this project and seeking new availability and commercialization of peptide.